Riskpilot← Back to searchSign inGet full accessRibocure Pharmaceuticals AB
ABActiveOrg 5593664377Vetenskapens Gränd 11Research and experimental development on natural sciences and engineering · NACE 7210Est. 202220-49 employees
Revenue 2024
SEK 87,5M
+44% vs 2023
EBITDA margin
6.5%
+248% vs 2023
Equity ratio
51.8%
Financial strength
Net profit 2024
SEK 2,7M
+343% vs 2023
| Revenue | SEK 87,5M | +44% |
| EBITDA | SEK 5,7M | +248% |
| Net profit | SEK 2,7M | +343% |
| Total assets | SEK 79,6M | +33% |
| Equity | SEK 41,3M | +7% |
| Employees | — | — |
Legal name
Ribocure Pharmaceuticals AB
Org number
5593664377
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
18 februari 2022
Share capital
SEK 1 253 000
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas ensam av Gan, Li Ming
Company purpose
Bolaget ska, direkt eller indirekt via dotterbolag, (i) bedriva forskning och klinisk utveckling och kliniska studier samt kommersialisera läkemedel, (ii) tillhandahålla tjänster (inklusive konsultation) avseende forskning och klinisk utveckling och kliniska studier samt kommersialisering av läkemedel, (iii) investera i verksamheter som bedriver forskning och klinisk utveckling och kliniska studier samt kommersialisering av läkemedel, (iv) bedriva affärsutveckling avseende in- och utlicensiering, (v) äga och förvalta lös och fast egendom samt (vi) bedriva därmed förenlig verksamhet.
Address
Vetenskapens Gränd 11
Email
li-ming.gan@ribocure.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 28 857 | 60 661 | 87 470 |
| Staff expenses | — | — | — |
| EBITDA | −824 | 1 638 | 5 701 |
| Depreciation & amort. | −28 | −1 129 | −2 886 |
| EBIT | −852 | 509 | 2 815 |
| Net financials | 972 | 317 | 630 |
| Profit before tax | 120 | 827 | 3 445 |
| Tax | −32 | −216 | −739 |
| Net profit | 88 | 611 | 2 706 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 34 156 | 59 868 | 79 626 |
| Equity | 28 960 | 38 511 | 41 283 |
| Long-term debt | 0 | 0 | 0 |
| Short-term debt | 5 196 | 21 357 | 38 343 |
| Total debt | 5 196 | 21 357 | 38 343 |
EBITDA margin
6.5%
This company
15.8%
Market median
-59% vs market
20222024
Equity ratio
51.8%
This company
38.2%
Market median
+36% vs market
20222024
Return on equity
6.6%
This company
18.4%
Market median
-64% vs market
20222024
Net profit margin
3.1%
This company
8.1%
Market median
-62% vs market
20222024
Asset turnover
1.10×
This company
1.12×
Market median
+2% vs market
20222024
Debt / equity
0.93×
This company
0.62×
Market median
+50% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LM Chief Executive Officer | Chief Executive Officer | 2022 |
NC Chief Auditor | Chief Auditor | 2024 |
| Former (1) | ||
MG Chief Auditor | Chief Auditor | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2025 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ribocure Pharmaceuticals AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Li Ming Gan | Chief Executive Officer | 0 companies |
| Mattias Gustaf Erik Olofson | Chief Auditor | 0 companies |
| Nina Charlotte Angard | Chief Auditor | 0 companies |
| Zicai Liang | Chairman | 0 companies |
| Kjell Erik Torne Selin | Board of Directors | 0 companies |
| Hong Yan Zhang | Board of Directors | 0 companies |